Old Versus New Neuroendocrine Tumor Imaging Agents

Hossein Jadvar, MD, PhD, MPH, MBA


August 02, 2016

68Ga-DOTATATE Compared With 111In-DTPA-Octroeotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-analysis

Deppen SA, Blume J, Bobbey AJ, et al
J Nucl Med. 2016;57:872-878


This systematic review and meta-analysis compared 68Ga-DOTATATE positron emission tomography (PET) with 111In-DTPA-pentetreotide (octreotide) scintigraphy in patients with pulmonary and gastroenteropancreatic neuroendocrine tumors.

A comprehensive search of data published between January 1999 and September 2015 yielded 42 eligible articles. 68Ga-DOTATATE was more sensitive than 111In-DTPA-octreotide and conventional imaging. The estimated sensitivity for 68Ga-DOTATATE was 90.9% (95% confidence interval, 81.4%-96.4%) and the specificity was 90.6% (95% confidence interval, 77.8%-96.1%). No major toxicity was reported; there were only rare minor adverse events.

The authors concluded that—given its superior image quality, lower radiation dosimetry, and more streamlined imaging acquisition and improved patient convenience (imaging 2 hours after 68Ga-DOTATATE injection compared with 2 or 3 days after 111In-DTPA-octreotide injection)—68Ga-DOTATATE should be used in preference over 111In-DTPA-octreotide where available.


Systematic reviews and meta-analysis make important contributions to the relevant literature,[1] and this timely investigation mined literature to compare 68Ga-DOTATATE PET (and PET/CT) versus 111In-DTPA-octreotide scintigraphy in patients with neuroendocrine tumors.

68Ga-DOTATATE PET was approved by the US Food and Drug Administration recently.[2] Although other reviews have been published on this imaging agent, the new study put 68Ga-DOTATATE head to head with the "historic" standard of reference, 111In-DTPA-scintigraphy.[3,4] In summary, it is quite evident that the time has come to replace "historic" with the "modern" standard of reference in this clinical setting.



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.